Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2021 Q1 earnings Read more ...
2 Pharma Stocks To Watch This Week One of the perks of investing in pharmaceutical stocks is that they offer strong growth prospects and solid dividends. You could make a pretty good investment any time in drugmakers if your investment horizon is long enough. Honestly, think about it. Just r...
Source: ClearBridge Investments Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Daiichi Sankyo ( OTCPK:DSNKY ) has entered into a strategic agreement with Syneos Health ( SYNH +1.0% ) to form a coalition for development of cancer therapies. More news on: Daiichi Sankyo Company, Limited, Syneos Health, Inc., Daiichi Sankyo Company, Limited, Healthcare stocks n...
Daiichi Sankyo Co Ltd (DSKYF) Q4 2019 Earnings Conference Call April 27, 2020, 03:00 ET Company Participants Sunao Manabe - President & Group CEO Wataru Takasaki - Executive Officer & Head, R&D Division Toshiaki Sai - CFO, EVP & Head, Corporate Strategy Confere...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q1 earnings Read more ...
Daiichi Sankyo ( DSNKY ) is an established player in the Japanese pharmaceutical sector, and may well have a winning drug in its pipeline for future profits. However, I am not convincing that this prospect justifies its current valuation. The prospect to which I refer is the DS-8201 drug, ma...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this Read more ...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
AstraZeneca (NYSE: AZN) recently impressed a crowd of oncologists at the annual San Antonio Breast Cancer Symposium with surprisingly good clinical trial results. In a nutshell, it looks like an experimental drug that the company licensed from Daiichi Sankyo (OTC: DSNKY) c...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...